REMEDi4ALL Building a Sustainable European Innovation Platform to Enhance the Repurposing of Medicines for All
- Coordinator
- Eatris Eric, Netherlands
- Runs
- 1 September 2022 to 31 August 2027
- Status
- Running
- EU funding
- €22.6m
- Total cost
- €22.6m
- Partners
- 28 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057442
What the project is doing
In the project's own words, from its summary on CORDIS.
REMEDi4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDi4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders.
The tools and processes developed assembled in REMEDi4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases. The REMEDi4ALL platform will operate a complete, harmonised and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach in a goal-oriented and patient-centric approach.
Working closely together with research funders and the patient community, REMEDi4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange.
REMEDi4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into the market, through its complete value chain and consensus-based policy development mission.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Eatris Eric | Amsterdam | Netherlands | Coordinator |
| Antikankerfonds - Fonds Anticancer-Anticancer Fund | Meise | Belgium | Participant |
| Medicines for Europe | Bruxelles / Brussel | Belgium | Participant |
| Bundesinstitut Fur Arzneimittel Und Medizinprodukte | Bonn | Germany | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts | Goettingen | Germany | Participant |
| Chemotargets SL | Barcelona | Spain | Participant |
| Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal | Madrid | Spain | Third party |
| Servicio Madrileno De Salud | Madrid | Spain | Participant |
| Teamit Institute S.l.u | Barcelona | Spain | Third party |
| Teamit Research S.l. | Barcelona | Spain | Participant |
| Helsingin Yliopisto | Helsinki | Finland | Participant |
| Ecrin European Clinical Research Infrastructure Network | Paris | France | Participant |
| Eurordis - Rare Diseases Europe | Paris | France | Participant |
| Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag | Budapest | Hungary | Participant |
| Dompe Farmaceutici SpA | Milano | Italy | Participant |
| Istituto Di Ricerche Farmacologiche Mario Negri | Milano | Italy | Participant |
| ISTITUTO NAZIONALE TUMORI Fondazione Pascale | Napoli | Italy | Participant |
| Istituto Ortopedico Rizzoli | Bologna | Italy | Participant |
| Zorgonderzoek Nederland Zon | Den Haag | Netherlands | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| Univerza V Ljubljani | Ljubljana | Slovenia | Participant |
| Beacon: for Rare Diseases Ltd | Cambridge | United Kingdom | Associatedpartner |
| Lifearc | London | United Kingdom | Associatedpartner |
| The University of Sheffield | Sheffield | United Kingdom | Associatedpartner |
| University College London | London | United Kingdom | Associatedpartner |
| University of Hull | Hull | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI